{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:47:06Z","timestamp":1793692026652,"version":"4.5.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.xphs.2021.09.038","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T15:19:33Z","timestamp":1632928773000},"page":"479-484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Topical Tacrolimus Progylcosomes Nano-Vesicles As a Potential Therapy for Experimental Dry Eye Syndrome"],"prefix":"10.1016","volume":"111","author":[{"family":"Mohammad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaidehi","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayabalan","family":"Nirmal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musarrat H.","family":"Warsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti","family":"Pandita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0890-769X","authenticated-orcid":false,"given":"Prashant","family":"Kesharwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav Kumar","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2021.09.038_bib0001","first-page":"75","article-title":"The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international Dry Eye WorkShop (2007)","volume":"5","author":"Lemp","year":"2007"},{"issue":"4968","key":"10.1016\/j.xphs.2021.09.038_bib0002","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.2200121","article-title":"Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase","volume":"249","author":"Tuerk","year":"1990","journal-title":"Science (80-)"},{"issue":"6","key":"10.1016\/j.xphs.2021.09.038_bib0003","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/bjophthalmol-2015-307094","article-title":"Incomplete response to artificial tears is associated with features of neuropathic ocular pain","volume":"100","author":"Galor","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.xphs.2021.09.038_bib0004","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S1542-0124(12)70290-2","article-title":"Corneal pain without stain: is it real?","volume":"7","author":"Rosenthal","year":"2009","journal-title":"Ocul Surf"},{"key":"10.1016\/j.xphs.2021.09.038_bib0005","first-page":"1","article-title":"Formulation development, optimization, and in vitro assessment of thermoresponsive ophthalmic pluronic F127-chitosan in situ tacrolimus gel","author":"Modi","year":"2021","journal-title":"J Biomater Sci Polym Ed"},{"issue":"2","key":"10.1016\/j.xphs.2021.09.038_bib0006","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.xphs.2020.10.060","article-title":"Amelioration of endotoxin-induced uveitis in rabbit by topical administration of tacrolimus proglycosome nano-vesicles","volume":"110","author":"Garg","year":"2021","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2021.09.038_bib0007","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ophtha.2003.05.035","article-title":"A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis","volume":"111","author":"Akpek","year":"2004","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.xphs.2021.09.038_bib0008","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1006\/exer.1998.0520","article-title":"Regulation of ocular mucin secretion by P2Y2 nucleotide receptors in rabbit and human conjunctiva","volume":"67","author":"Jumblatt","year":"1998","journal-title":"Exp Eye Res"},{"issue":"1","key":"10.1016\/j.xphs.2021.09.038_bib0009","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1167\/iovs.03-0903","article-title":"Differential regulation of membrane-associated mucins in the human ocular surface epithelium","volume":"45","author":"Hori","year":"2004","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.xphs.2021.09.038_bib0010","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/ICO.0b013e31823f8c9b","article-title":"Clinical treatment of dry eye using 0.03% tacrolimus eye drops","volume":"31","author":"Moscovici","year":"2012","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.xphs.2021.09.038_bib0011","doi-asserted-by":"crossref","DOI":"10.1186\/s40662-017-0072-z","article-title":"Topical tacrolimus in anterior segment inflammatory disorders","volume":"4","author":"Shoughy","year":"2017","journal-title":"Eye Vis"},{"issue":"5","key":"10.1016\/j.xphs.2021.09.038_bib0012","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/bmt.2009.249","article-title":"Topical 0.03% tacrolimus ointment in the management of ocular surface inflammation in chronic GVHD","volume":"45","author":"Tam","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"13\u201314","key":"10.1016\/j.xphs.2021.09.038_bib0013","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.drudis.2012.03.006","article-title":"Therapeutic stratagems for vascular degenerative disorders of the posterior eye","volume":"17","author":"Jain","year":"2012","journal-title":"Drug Discov Today"},{"issue":"16","key":"10.1016\/j.xphs.2021.09.038_bib0014","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1016\/j.biomaterials.2012.02.033","article-title":"A review of glycosylated carriers for drug delivery","volume":"33","author":"Jain","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.xphs.2021.09.038_bib0015","first-page":"1921","article-title":"Liposomes containing bile salts as novel ocular delivery systems for tacrolimus (FK506): in vitro characterization and improved corneal permeation","volume":"8","author":"Dai","year":"2013","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.xphs.2021.09.038_bib0016","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejps.2014.05.020","article-title":"Proniosome-derived niosomes for tacrolimus topical ocular delivery: in vitro cornea permeation, ocular irritation, and in vivo anti-allograft rejection","volume":"62","author":"Li","year":"2014","journal-title":"Eur J Pharm Sci"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2021.09.038_bib0017","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijpharm.2011.04.027","article-title":"Spanlastics-A novel nanovesicular carrier system for ocular delivery","volume":"413","author":"Kakkar","year":"2011","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2021.09.038_bib0018","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.colsurfb.2016.03.061","article-title":"The potential use of novel chitosan-coated deformable liposomes in an ocular drug delivery system","volume":"143","author":"Chen","year":"2016","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"71","key":"10.1016\/j.xphs.2021.09.038_bib0019","doi-asserted-by":"crossref","first-page":"43629","DOI":"10.1039\/D0RA07640F","article-title":"Formulation development,: in vitro and in vivo evaluation of chitosan engineered nanoparticles for ocular delivery of insulin","volume":"10","author":"Rathore","year":"2020","journal-title":"RSC Adv"},{"key":"10.1016\/j.xphs.2021.09.038_bib0020","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jcis.2016.08.018","article-title":"Moxifloxacin loaded gelatin nanoparticles for ocular delivery: formulation and in-vitro, in-vivo evaluation","volume":"483","author":"Mahor","year":"2016","journal-title":"J Colloid Interface Sci"},{"key":"10.1016\/j.xphs.2021.09.038_bib0021","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.colsurfb.2017.05.049","article-title":"Proglycosomes: a novel nano-vesicle for ocular delivery of tacrolimus","volume":"157","author":"Garg","year":"2017","journal-title":"Colloids Surfaces B Biointerfaces"},{"issue":"3","key":"10.1016\/j.xphs.2021.09.038_bib0022","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000055537","article-title":"Development of a simple dry eye model in the albino rabbit and evaluation of some tear substitutes","volume":"31","author":"Burgalassi","year":"1999","journal-title":"Ophthalmic Res"},{"issue":"5","key":"10.1016\/j.xphs.2021.09.038_bib0023","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1167\/iovs.07-0720","article-title":"A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride","volume":"49","author":"Xiong","year":"2008","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.xphs.2021.09.038_bib0024","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.jepm.2018.09.015","article-title":"Measurement of tear production using schirmer tear test and standardized endodontic absorbent paper points in ferrets (Mustela Putorius Furo)","volume":"29","author":"Lim\u00f3n","year":"2019","journal-title":"J Exot Pet Med"},{"issue":"8","key":"10.1016\/j.xphs.2021.09.038_bib0025","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/02713683.2018.1457164","article-title":"Tear film stability and tear break up time (TBUT) in laboratory rabbits\u2014a systematic review","volume":"43","author":"Doughty","year":"2018","journal-title":"Curr Eye Res"},{"issue":"6","key":"10.1016\/j.xphs.2021.09.038_bib0026","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.acthis.2011.10.004","article-title":"Immunohistochemical expression of matrix metalloproteinases in the rabbit corneal epithelium upon UVA and UVB irradiation","volume":"114","author":"Ardan","year":"2012","journal-title":"Acta Histochem"},{"issue":"October","key":"10.1016\/j.xphs.2021.09.038_bib0027","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jtos.2020.10.003","article-title":"Matrix metalloproteinase 9 positivity predicts long term decreased tear production","volume":"19","author":"Soifer","year":"2021","journal-title":"Ocul Surf"},{"issue":"5","key":"10.1016\/j.xphs.2021.09.038_bib0028","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/eye.1995.149","article-title":"Infrared thermography of the tear film in dry eye","volume":"9","author":"Tullo","year":"1995","journal-title":"Eye"},{"key":"10.1016\/j.xphs.2021.09.038_bib0029","first-page":"581","article-title":"Diagnosis of dry eye disease and emerging technologies","volume":"8","author":"Zeev","year":"2014","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.xphs.2021.09.038_bib0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1001\/archopht.1969.00990020012003","article-title":"Diagnostic tests in the sicca syndrome","volume":"82","author":"Van Bijsterveld","year":"1969","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.xphs.2021.09.038_bib0031","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/02713680701198742","article-title":"Evaluation of ocular surface changes in a rabbit dry eye model using a modified impression cytology technique","volume":"32","author":"Altinors","year":"2007","journal-title":"Curr Eye Res"},{"issue":"8","key":"10.1016\/j.xphs.2021.09.038_bib0032","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/ICO.0b013e31823f8c9b","article-title":"Clinical treatment of dry eye using 0.03% tacrolimus eye drops","volume":"31","author":"Moscovici","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.xphs.2021.09.038_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2021.03.011","article-title":"The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer","author":"Singh","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.xphs.2021.09.038_bib0034","article-title":"Immune checkpoint inhibitors: a promising anticancer therapy","author":"Singh","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.xphs.2021.09.038_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106417","article-title":"Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care","volume":"83","author":"Singh","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"10.1016\/j.xphs.2021.09.038_bib0036","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.mehy.2013.08.007","article-title":"Topical tacrolimus nanoemulsion, a promising therapeutic approach for uveitis","volume":"81","author":"Garg","year":"2013","journal-title":"Med Hypotheses"},{"issue":"4","key":"10.1016\/j.xphs.2021.09.038_bib0037","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1463-5224.2005.00390.x","article-title":"Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca","volume":"8","author":"Berdoulay","year":"2005","journal-title":"Vet Ophthalmol"},{"issue":"2","key":"10.1016\/j.xphs.2021.09.038_bib0038","first-page":"240","article-title":"Dry eye: an inflammatory ocular disease","volume":"9","author":"Hessen","year":"2014","journal-title":"J Ophthalmic Vis Res"},{"issue":"1","key":"10.1016\/j.xphs.2021.09.038_bib0039","first-page":"24","article-title":"Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye","volume":"131","author":"Sambursky","year":"2013","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.xphs.2021.09.038_bib0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00280-005-0155-8","article-title":"Antiproliferative and antiproteolytic activity of pentoxifylline in cultures of B16F10 melanoma cells","volume":"58","author":"Dua","year":"2006","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921005256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921005256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:35:41Z","timestamp":1758360941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354921005256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0022354921005256"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2021.09.038","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical Tacrolimus Progylcosomes Nano-Vesicles As a Potential Therapy for Experimental Dry Eye Syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2021.09.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}